ST. LOUIS, Nov. 14, 2025 (GLOBE NEWSWIRE) — The Marketing Alliance, Inc. (OTC: MAAL) (“TMA” or the “Company”), announced its financial results today for its fiscal 2026 second quarter ended September 30, 2025. Q2 2026 Financial Key Items (all comparisons to the prior year quarter)Revenues from operations were $4,668,836 compared to $4,983,950, a decrease of over 6% which was almost entirely in the construction business Operating income from continuing operations of $149,507 compared to $486,639 in the prior year quarter Net income was $263,407 or $0.04 per share in the quarter compared to $401,511 or $0.05 per share in the prior year quarter During the quarter the Company repurchased 166,146 shares, and subsequent to the end of quarter the Company repurchased an additional 50,000 shares. Repurchases under the program may be made...

FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study EB613 Phase 2 Data Demonstrating Consistent Efficacy across Younger Post-Menopausal Women with Osteoporosis and its Impact on Trabecular and Cortical Bone Indices, Highlighted at NAMS and ASBMR Next-Generation EB613 Remains on Track for Phase 1 Initiation in Late 2025 Pre-Clinical Data for Oral OXM in Obesity and Oral GLP-2 in Short Bowel Syndrome in Collaboration with OPKO Presented at ENDO2025 and ESPEN JERUSALEM, Nov. 14, 2025 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended September 30, 2025. “Our achievements this quarter are testament to Entera’s leadership...

CALABASAS, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced financial results for the quarter ended September 30, 2025, and provided an update on recent operational achievements and upcoming milestones. Third Quarter & Recent Corporate HighlightsMiddle East – NuroMENA, the UAE-based subsidiary, advanced its regional partnerships by appointing His Highness Sheikh Nahyan bin Zayed Al Nahyan as Executive Chairman, signing a Master Services Agreement with M42’s IROS, and completing ADGM incorporation. The company also progressed a $50 million strategic partnership with Quazar Investment, strengthening Abu Dhabi–US collaboration in...

ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) — Trust Stamp (Nasdaq: IDAI) announced that:It filed its Q3 10-Q report for the nine months ended September 30, 2025 after the Nasdaq market closed on November 14th, 2025. Net recognised revenue for the three months ended September 30, 2025 was $0.87 million, an increase of 71% from $0.51 million for the corresponding period in 2024. An additional $0.23 million of revenue was received from QID and fully earned but subject to deferred recognition under ASC 606. The majority of the increase ($313 thousand) was attributable to the Company’s S&P 500 bank customer resulting from the Company entering into a contract amendment and extension with this customer extending the term until May 31, 2031 (subject to a right for the customer to cancel for convenience on 6 months notice), with...

BOSTON and ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended September 30, 2025 and highlighted recent developments. “During our third quarter of 2025, we continued to position the Company to advance IKT-001 toward a late-stage clinical trial in PAH,” said Mark Iwicki, Chief Executive Officer of Inhibikase. “We expect to initiate our Phase 2b clinical study of IKT-001, our prodrug of imatinib mesylate, in PAH during the fourth quarter of 2025.” Recent Developments:Advancement of IKT-001 as a therapy in PAH:The proposed Phase 2b IMPROVE-PAH trial is...

Third Quarter 2025 HighlightsXBP Europe Holdings, Inc. (“XBP Europe”) finalized the acquisition of Exela Technologies BPA, LLC (“Exela BPA”) and changed its name to XBP Global Holdings, Inc. on July 29, 2025 XBP Europe issued approximately 81.8 million shares for an equity valuation of the combined company of $585.7 million, or $4.98/share     Reported revenue1 totaled $209.1 million, a decline of 10.4% year-over-year Combined Pro Forma Revenue2 totaled $220.4 million, a decline of 18.1% year-over-year Gross margin on a reported basis was 22.0%, a 310 basis point increase year-over-year Pro Forma Gross Margin2 of 21.9%, a 190 basis point increase year-over-year Pro Forma Adjusted EBITDA2,3 of $24.7 million, an increase of 7.4% year-over-yearIRVING, Texas, Nov. 14, 2025 (GLOBE NEWSWIRE) — XBP Global Holdings, Inc. (“XBP Global”...

– FDA Approval to Advance Final FemBloc® Trial with Clear Pathway to Potentially Achieve U.S. FDA Approval – – $12 Million Financing Strengthens Balance Sheet and Extends Cash Runway – ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results for the third quarter of 2025. Corporate Highlights from 3Q 2025Announced second partner order for FemBloc in Europe Announced FDA IDE approval to continue enrollment in final phase of the FINALE pivotal trial for FemBloc Announced a definitive agreement for the issuance of $12 million in secured convertible notes and accompanying warrants for total potential funding of $58 million, if all warrants are...

ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) — Atlantic American Corporation (Nasdaq- AAME) today reported net income of $0.6 million, or $0.02 per diluted share, for the three month period ended September 30, 2025, compared to net loss of ($2.0) million, or ($0.10) per diluted share, for the three month period ended September 30, 2024. The Company had net income of $4.7 million, or $0.22 per diluted share, for the nine month period ended September 30, 2025, compared to net loss of ($4.7) million, or ($0.24) per diluted share, for the nine month period ended September 30, 2024. The increase in net income for the three month and nine month periods ended September 30, 2025 was primarily the result of increases in premium revenue within the automobile liability, inland marine and automobile physical damage lines of business in the property...

BETHLEHEM, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) — On November 13, 2025, Embassy Bancorp, Inc. (OTCQX: EMYB) (the “Company”) filed its Quarterly Report on Form 10-Q for the period ended September 30, 2025, a copy of which can be found at https://investors.embassybank.com/sec-filings/documents/default.aspx. Highlights of the filing, which includes consolidated financial information of the Company and Embassy Bank For the Lehigh Valley (the “Bank”), the Company’s wholly owned subsidiary, include:Cash and cash equivalents on hand of $108.0 million at September 30, 2025, or 6.1% of total assets. Deposits of $1.62 billion at September 30, 2025, an increase of $67.6 million, or 4.4%, from $1.55 billion at December 31, 2024. The Company does not have any brokered deposits. Short term borrowings of $15.6 million at December 31, 2024, were...

WARREN, N.J., Nov. 14, 2025 (GLOBE NEWSWIRE) — Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced the filing of its quarterly report on Form 10-Q for the quarter ended September 30, 2025, highlighting continued capital-efficient execution at a time when sustainability has become what the Company believes a defining challenge for the biotechnology industry. Tevogen reported a loss from operations calculated in accordance with U.S. GAAP of $5.7 million for the three months ended September 30, 2025, a reduction of 6% as compared to the three months ended September 30, 2024. The Company reported a 51% reduction in operating loss, totaling $21.5 million for the nine months ended September 30, 2025, compared to the same period in 2024. Tevogen Bio Holdings Inc. Unaudited Consolidated Statements of Operations    Three...